Navigation Links
NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR
Date:6/13/2008

SOPHIA ANTIPOLIS, France, June 13 /PRNewswire-FirstCall/ --

NicOx S.A. (Euronext Paris: COX) today announced an additional analysis of the blood pressure data from the 301 phase 3 study, showing a statistically significant difference between naproxcinod and naproxen in terms of the mean change from baseline in systolic and diastolic blood pressure at week 13 (p<0.05 for 3 out of 4 comparisons). Commonly used Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as naproxen, have the tendency to raise blood pressure to an extent that may increase the rate of serious cardiovascular adverse events. The new results are being presented today at the 2008 European League Against Rheumatism (EULAR) Congress in Paris. Naproxcinod is NicOx' lead investigational drug and the first compound in the Cyclooxygenase-Inhibiting Nitric Oxide Donator (CINOD) class, which NicOx is developing for the treatment of the signs and symptoms of osteoarthritis.

Positive top-line efficacy results from the 301 study have been previously announced, showing that both doses of naproxcinod (750 mg and 375 mg bid) were superior to placebo on all three co-primary efficacy endpoints (p<0.001). Patients' blood pressure was also measured in the study, with a well defined standardized approach where investigators took office blood pressure measurements (OBPM) at each patient visit to the clinical site. The OBPM changes from baseline at week 13 were predefined safety endpoints of the study and the statistical analysis announced today was conducted on a post hoc basis.

Pascal Pfister MD, Chief Scientific Officer and Head of Research and Development at NicOx, said: "We are very pleased to be presenting these important data from our most advanced CINOD at EULAR. We believe the results of the post hoc statistical analysis on blood pressure are particularly encouraging, as the 301 study was not powered to show a significant difference between naproxcinod and naproxen on this safety en
'/>"/>

SOURCE NicOx S.A.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
2. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
3. Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs
4. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
5. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
6. NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020
7. NicOx Naproxcinod Phase 3 Results Presented at American College of Rheumatology
8. NicOx Naproxcinod ABPM Data Presented at American Heart Association
9. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
10. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
11. Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... N.J. , May 4, 2015 Thirty-six ... percent seek help. During May – National Hearing Month ... loss could be missing out on the sounds of ... the trees. To ensure that you won,t ... that color our world, Oticon, Inc. offers practical advice: ...
(Date:5/4/2015)... WORCESTER, Mass. and TORONTO ... ( www.generex.com ) (OTCQB:GNBT) today announced that it intends ... securities it receives upon completion of a definitive licensing ... to Smoofi, Inc. ( www.smoofi.com ) (OTCQB:SMFI). ... a non-binding letter of intent in respect of the ...
(Date:5/4/2015)... , May 4, 2015 RadiologyAuction will have their ... video and product demonstrations at the end of the ... such as Kodak and Fuji Cr,s, Agfa and Sony, ... the first event. Various imaging equipment will be available ... After years of buying and selling imaging ...
Breaking Medicine Technology:It's Better Hearing Month 2Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 2Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 3Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 4Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 5RadiologyAuction Announces Event Starting On May 5th 2
... 16, Uroplasty, Inc. (Nasdaq: UPI ), ... innovative proprietary products to treat voiding dysfunctions, announced today ... Jiwani, Uroplasty,s Vice President and CFO, will present the ... Hunter Securities Inaugural Healthcare Conference at 3:30  PM PDT ...
... a crippling disease worldwide, with an estimated eight million sufferers ... a suit of rusty armour," with unrelenting, razor-like pain. ... reverse the degenerative condition. However a discovery made ... hold the key to not only halting the degenerative process, ...
Cached Medicine Technology:Uroplasty to Present at Global Hunter Securities Inaugural Healthcare Conference 2New Hope For Joint Pain Sufferers 2New Hope For Joint Pain Sufferers 3
(Date:5/4/2015)... LiveSchool ” was featured on NewsWatch as part of ... latest and coolest applications on the market for iOS, ... and technology expert, conducted the app review and shared ... students with good behavior. , Positive re-enforcement is more ... And the good people at LiveSchool have taken note ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 The opportunity for ... full life are the motivating forces behind The Fairy Godmother ... psychologist and author Amy L. Stark. , The inspiration for ... girl next door comes from Stark’s desire to be a ... been a fairy godmother to my neighbors’ children since they ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 The U.S. ... baby boomers join the ranks of senior citizens (1) ... on an already over-burdened healthcare system. Additionally, as older ... to replace them. Per the U.S. Census Bureau, the ... to increase 75% by 2050 while those 25 to ...
(Date:5/4/2015)... OK and Seattle, WA (PRWEB) May 04, 2015 ... the formation of a collaboration to facilitate development of ... of ophthalmic disorders that lead to blindness, including Diabetic ... the MiDROPS™ formulation platform developed by EyeCRO, which can ... eye via a topical eyedrop. , Under the ...
(Date:5/4/2015)... 04, 2015 New findings released today ... Association (ABTA) show that people diagnosed with a brain ... options, including clinical trials, at the time of diagnosis, ... difficult decisions about their course of treatment. The release ... first nationwide brain tumor volunteer network, the ABTA CommYOUnity™, ...
Breaking Medicine News(10 mins):Health News:An Application for Teachers to Reward Students with Good Behavior Was Featured on NewsWatch Television 2Health News:Introducing New Children’s Book The Fairy Godmother Next Door 2Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 2Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 3Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 4Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 2Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 3Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 2Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 3
... Highlights, - Revenue for the first quarter was $480.6 million, up 7.6% from ... ... ("FOI") grew 7.2% for the twelve, months ended March 31, 2008 over ... was $38.6 million, or $0.38,per outstanding common share, a 19% increase over the ...
... project as innovative in terms of energy efficiency and ... awarded nearly $27 million in funding for a new ... (USC). USC was one of 12 California institutions considered ... million to build stem cell research facilities throughout California. ...
... May 8, 2008 at 2:00 pm ET, MISSION ... ENSG ), the parent company of the Ensign(TM) ... today reported results for the first quarter of fiscal ... ) Highlights of the First Quarter Include:, ...
... 7 Conseco, Inc. (NYSE: CNO ),today reported ... set a new quarterly sales record with an increase ... Prieur said. "This performance included,an 11% increase at Bankers ... increase in total sales including new product offerings) of ...
... , Ottawa (May 7, 2008) The Honourable ... the Canadian Institutes of Health Research (CIHR) for 764 ... Minister Clement was joined by Dr. Patrick McGrath, a ... neonatologist and CIHR-funded researcher from the University of Alberta, ...
... 7 Dr. Hugo Stephenson, founder and ... drug safety, today,presented new insight about the ... the U.S. Food and Drug Administration (FDA). ... (rosuvastatin),Lipitor (atorvastatin), and Zocor (simvastatin) all warn ...
Cached Medicine News:Health News:Brookdale Announces First Quarter 2008 Results 2Health News:Brookdale Announces First Quarter 2008 Results 3Health News:Brookdale Announces First Quarter 2008 Results 4Health News:Brookdale Announces First Quarter 2008 Results 5Health News:Brookdale Announces First Quarter 2008 Results 6Health News:Brookdale Announces First Quarter 2008 Results 7Health News:Brookdale Announces First Quarter 2008 Results 8Health News:Brookdale Announces First Quarter 2008 Results 9Health News:Brookdale Announces First Quarter 2008 Results 10Health News:Brookdale Announces First Quarter 2008 Results 11Health News:Brookdale Announces First Quarter 2008 Results 12Health News:Brookdale Announces First Quarter 2008 Results 13Health News:Brookdale Announces First Quarter 2008 Results 14Health News:Brookdale Announces First Quarter 2008 Results 15Health News:Brookdale Announces First Quarter 2008 Results 16Health News:Brookdale Announces First Quarter 2008 Results 17Health News:Brookdale Announces First Quarter 2008 Results 18Health News:Brookdale Announces First Quarter 2008 Results 19Health News:Brookdale Announces First Quarter 2008 Results 20Health News:Brookdale Announces First Quarter 2008 Results 21Health News:Brookdale Announces First Quarter 2008 Results 22Health News:USC receives nearly $27 million in funding for new stem cell research facility 2Health News:The Ensign Group, Inc. Reports First Quarter 2008 Earnings 2Health News:The Ensign Group, Inc. Reports First Quarter 2008 Earnings 3Health News:The Ensign Group, Inc. Reports First Quarter 2008 Earnings 4Health News:The Ensign Group, Inc. Reports First Quarter 2008 Earnings 5Health News:The Ensign Group, Inc. Reports First Quarter 2008 Earnings 6Health News:The Ensign Group, Inc. Reports First Quarter 2008 Earnings 7Health News:The Ensign Group, Inc. Reports First Quarter 2008 Earnings 8Health News:The Ensign Group, Inc. Reports First Quarter 2008 Earnings 9Health News:The Ensign Group, Inc. Reports First Quarter 2008 Earnings 10Health News:Conseco Reports First Quarter Results 2Health News:Conseco Reports First Quarter Results 3Health News:Conseco Reports First Quarter Results 4Health News:Conseco Reports First Quarter Results 5
Pocket-sized instrument, powered by two AA-sized alkaline batteries. Built-in throat illuminator, rectangular viewing lens for instrumentation under magnification....
The Pneumatic Consulting Otoscope provides two viewing lenses for dual observation of the tympanic membrane. Sealed system for pneumnatic otoscopy and rotatable head for left- and right-sided viewin...
Provides 30% more magnification and twice the field of view. Adjustable focus, with insufflator bulb....
... to laser treatment of AMD patients ... compares to the Opal Photoactivator from,Lumenis. ... (verteporfin for injection) therapy, the Opal ... any other laserfeatures,that ensure the highest ...
Medicine Products: